You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRuxolitinib
Accession NumberDB08877
TypeSmall Molecule
GroupsApproved
DescriptionRuxolitinib is a janus-associated kinase inhibitor indicated to treat bone marrow cancer, specifically intermediate or high-risk myelofibrosis. FDA approved on November 16, 2011.
Structure
Thumb
Synonyms
INCB018424
INCB424
External Identifiers
  • INCB 18424
  • INCB018424
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
JakafiTablet5 mg/1OralIncyte Corporation2011-11-16Not applicableUs
JakafiTablet25 mg/1OralIncyte Corporation2011-11-16Not applicableUs
JakafiTablet10 mg/1OralIncyte Corporation2011-11-16Not applicableUs
JakafiTablet15 mg/1OralIncyte Corporation2011-11-16Not applicableUs
JakafiTablet20 mg/1OralIncyte Corporation2011-11-16Not applicableUs
JakaviTablet20 mgOralNovartis Pharmaceuticals Canada Inc2012-07-19Not applicableCanada
JakaviTablet20 mgOralNovartis Europharm Ltd2012-08-23Not applicableEu
JakaviTablet5 mgOralNovartis Europharm Ltd2012-08-23Not applicableEu
JakaviTablet10 mgOralNovartis Europharm Ltd2012-08-23Not applicableEu
JakaviTablet10 mgOralNovartis Pharmaceuticals Canada Inc2015-04-15Not applicableCanada
JakaviTablet20 mgOralNovartis Europharm Ltd2012-08-23Not applicableEu
JakaviTablet15 mgOralNovartis Europharm Ltd2012-08-23Not applicableEu
JakaviTablet5 mgOralNovartis Pharmaceuticals Canada Inc2012-07-19Not applicableCanada
JakaviTablet10 mgOralNovartis Europharm Ltd2012-08-23Not applicableEu
JakaviTablet5 mgOralNovartis Europharm Ltd2012-08-23Not applicableEu
JakaviTablet20 mgOralNovartis Europharm Ltd2012-08-23Not applicableEu
JakaviTablet15 mgOralNovartis Europharm Ltd2012-08-23Not applicableEu
JakaviTablet15 mgOralNovartis Pharmaceuticals Canada Inc2012-07-19Not applicableCanada
JakaviTablet5 mgOralNovartis Europharm Ltd2012-08-23Not applicableEu
JakaviTablet10 mgOralNovartis Europharm Ltd2012-08-23Not applicableEu
JakaviTablet15 mgOralNovartis Europharm Ltd2012-08-23Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Ruxolitinib Phosphate
Thumb
  • InChI Key: JFMWPOCYMYGEDM-XFULWGLBSA-N
  • Monoisotopic Mass: 404.136189702
  • Average Mass: 404.3602
DBSALT000156
Categories
UNII82S8X8XX8H
CAS number941678-49-5
WeightAverage: 306.365
Monoisotopic: 306.159294606
Chemical FormulaC17H18N6
InChI KeyHFNKQEVNSGCOJV-OAHLLOKOSA-N
InChI
InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1
IUPAC Name
(3R)-3-cyclopentyl-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)propanenitrile
SMILES
N#CC[[email protected]](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
Pharmacology
IndicationTreatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis. [Lexicomp] Myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue).
Structured Indications
PharmacodynamicsThe mean half-maximal inhibitory concentration (IC50) for JAK 1 and JAK 2 are 2.8 nmol/L and 3.3 nmol/L respectively. After administration of ruxolitinib, a decrease in levels of phosphorylated STAT (marker for JAK activity) in a dose-dependent manner can be observed. Pharmacodynamic resistance has not been observed.
Mechanism of actionRuxolitinib is a kinase inhibitor that is selective for the Janus Associated Kinases (JAK) 1 and 2. These kinases are responsible for the mediation of cytokine and growth factor signalling which in turn effect immune function and hematopoiesis. The signalling process involves signal transducers and transcription activators (STAT) which modulate gene expression. Patients with myelofibrosis have abnormal JAK1 and JAK2 activity thus ruxolitinib works to regulate this.
TargetKindPharmacological actionActionsOrganismUniProt ID
Tyrosine-protein kinase JAK1Proteinyes
inhibitor
HumanP23458 details
Tyrosine-protein kinase JAK2Proteinyes
inhibitor
HumanO60674 details
Related Articles
AbsorptionAbsorption is rapid and is not affected by food. Cmax, 15 mg, healthy subject = 649 nmol/L; Tmax, 15 mg, healthy subject = 1.5 hours; Ruxolitinib does not accumulate significantly.
Volume of distribution

Terminal phase volume of distribution, 15 mg, healthy subject = 76.6 L.

Protein binding97% protein bound, primarily to albumin.
Metabolism

Ruxolitinib is metabolized by CYP3A4. Less potent active metabolites forms as a result.

Route of eliminationEliminated via urine (74%, <1% as unchanged drug) and feces (22%, <1% as unchanged drug).
Half lifeMean elimination half-life, 15 mg, healthy subject = 2.8 hours.
Clearance

15 mg, healthy subject = 18.7 L/h.

ToxicityThrombocytopenia was the dose-limiting toxicity.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololRuxolitinib may increase the bradycardic activities of Acebutolol.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Ruxolitinib.Approved
ALT-110The risk or severity of adverse effects can be increased when Ruxolitinib is combined with ALT-110.Investigational
AmiodaroneThe serum concentration of Ruxolitinib can be increased when it is combined with Amiodarone.Approved, Investigational
AnvirzelAnvirzel may decrease the cardiotoxic activities of Ruxolitinib.Investigational
AprepitantThe serum concentration of Ruxolitinib can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Ruxolitinib can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololRuxolitinib may increase the bradycardic activities of Atenolol.Approved
AtomoxetineThe metabolism of Ruxolitinib can be decreased when combined with Atomoxetine.Approved
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Ruxolitinib.Investigational
BendroflumethiazideRuxolitinib may increase the bradycardic activities of Bendroflumethiazide.Approved
BeractantRuxolitinib may increase the bradycardic activities of Beractant.Approved
BetaxololRuxolitinib may increase the bradycardic activities of Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Ruxolitinib.Approved, Investigational
BexaroteneThe serum concentration of Ruxolitinib can be decreased when it is combined with Bexarotene.Approved, Investigational
BisoprololRuxolitinib may increase the bradycardic activities of Bisoprolol.Approved
BoceprevirThe serum concentration of Ruxolitinib can be increased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Ruxolitinib can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ruxolitinib can be decreased when it is combined with Bosentan.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ruxolitinib.Approved
CalfactantRuxolitinib may increase the bradycardic activities of Calfactant.Approved
CarbamazepineThe metabolism of Ruxolitinib can be increased when combined with Carbamazepine.Approved, Investigational
CarteololRuxolitinib may increase the bradycardic activities of Carteolol.Approved
CarvedilolRuxolitinib may increase the bradycardic activities of Carvedilol.Approved, Investigational
CDX-110The risk or severity of adverse effects can be increased when Ruxolitinib is combined with CDX-110.Investigational
CeritinibThe serum concentration of Ruxolitinib can be increased when it is combined with Ceritinib.Approved
ClarithromycinThe serum concentration of Ruxolitinib can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Ruxolitinib can be decreased when combined with Clemastine.Approved
ClonidineRuxolitinib may increase the bradycardic activities of Clonidine.Approved
ClotrimazoleThe metabolism of Ruxolitinib can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Ruxolitinib is combined with Clozapine.Approved
CobicistatThe serum concentration of Ruxolitinib can be increased when it is combined with Cobicistat.Approved
ConivaptanThe serum concentration of Ruxolitinib can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibRuxolitinib may increase the bradycardic activities of Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Ruxolitinib.Approved, Investigational
CyclosporineThe metabolism of Ruxolitinib can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Ruxolitinib can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe serum concentration of Ruxolitinib can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Ruxolitinib can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Ruxolitinib can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Ruxolitinib can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Ruxolitinib.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Ruxolitinib.Approved
DexamethasoneThe serum concentration of Ruxolitinib can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineRuxolitinib may increase the bradycardic activities of Dexmedetomidine.Approved, Vet Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Ruxolitinib.Approved
DigoxinRuxolitinib may increase the bradycardic activities of Digoxin.Approved
DihydroergotamineThe metabolism of Ruxolitinib can be decreased when combined with Dihydroergotamine.Approved
DiltiazemRuxolitinib may increase the bradycardic activities of Diltiazem.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ruxolitinib.Approved, Investigational
DonepezilRuxolitinib may increase the bradycardic activities of Donepezil.Approved
DoxycyclineThe metabolism of Ruxolitinib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneRuxolitinib may increase the bradycardic activities of Dronedarone.Approved
EfavirenzThe serum concentration of Ruxolitinib can be decreased when it is combined with Efavirenz.Approved, Investigational
EnzalutamideThe serum concentration of Ruxolitinib can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Ruxolitinib can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Ruxolitinib can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololRuxolitinib may increase the bradycardic activities of Esmolol.Approved
EtravirineThe serum concentration of Ruxolitinib can be decreased when it is combined with Etravirine.Approved
FingolimodRuxolitinib may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluconazoleThe serum concentration of Ruxolitinib can be increased when it is combined with Fluconazole.Approved
FluvoxamineThe metabolism of Ruxolitinib can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Ruxolitinib can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ruxolitinib can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Ruxolitinib can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Ruxolitinib can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Ruxolitinib is combined with G17DT.Investigational
GalantamineRuxolitinib may increase the bradycardic activities of Galantamine.Approved
GI-5005The risk or severity of adverse effects can be increased when Ruxolitinib is combined with GI-5005.Investigational
GuanfacineRuxolitinib may increase the bradycardic activities of Guanfacine.Approved, Investigational
IdelalisibThe serum concentration of Ruxolitinib can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Ruxolitinib can be decreased when combined with Imatinib.Approved
IndinavirThe serum concentration of Ruxolitinib can be increased when it is combined with Indinavir.Approved
INGN 201The risk or severity of adverse effects can be increased when Ruxolitinib is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Ruxolitinib is combined with INGN 225.Investigational
IsavuconazoniumThe metabolism of Ruxolitinib can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Ruxolitinib can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Ruxolitinib can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineRuxolitinib may increase the bradycardic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Ruxolitinib can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe serum concentration of Ruxolitinib can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolRuxolitinib may increase the bradycardic activities of Labetalol.Approved
LanreotideRuxolitinib may increase the bradycardic activities of Lanreotide.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Ruxolitinib is combined with Leflunomide.Approved, Investigational
LevobunololRuxolitinib may increase the bradycardic activities of Levobunolol.Approved
LopinavirThe serum concentration of Ruxolitinib can be increased when it is combined with Lopinavir.Approved
LovastatinThe metabolism of Ruxolitinib can be decreased when combined with Lovastatin.Approved, Investigational
LucinactantRuxolitinib may increase the bradycardic activities of Lucinactant.Approved
LuliconazoleThe serum concentration of Ruxolitinib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Ruxolitinib can be increased when combined with Lumacaftor.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Ruxolitinib.Withdrawn
MethyldopaRuxolitinib may increase the bradycardic activities of Methyldopa.Approved
MetipranololRuxolitinib may increase the bradycardic activities of Metipranolol.Approved
MetoprololRuxolitinib may increase the bradycardic activities of Metoprolol.Approved, Investigational
MifepristoneThe serum concentration of Ruxolitinib can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Ruxolitinib can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Ruxolitinib can be decreased when it is combined with Modafinil.Approved, Investigational
NadololRuxolitinib may increase the bradycardic activities of Nadolol.Approved
NafcillinThe serum concentration of Ruxolitinib can be decreased when it is combined with Nafcillin.Approved
NatalizumabThe risk or severity of adverse effects can be increased when Ruxolitinib is combined with Natalizumab.Approved, Investigational
NebivololRuxolitinib may increase the bradycardic activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Ruxolitinib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Ruxolitinib can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Ruxolitinib can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Ruxolitinib can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Ruxolitinib can be decreased when combined with Nilotinib.Approved, Investigational
OctreotideRuxolitinib may increase the bradycardic activities of Octreotide.Approved, Investigational
OlaparibThe metabolism of Ruxolitinib can be decreased when combined with Olaparib.Approved
OsimertinibThe serum concentration of Ruxolitinib can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Ruxolitinib.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ruxolitinib.Approved, Vet Approved
PalbociclibThe serum concentration of Ruxolitinib can be increased when it is combined with Palbociclib.Approved
PasireotideRuxolitinib may increase the bradycardic activities of Pasireotide.Approved
PenbutololRuxolitinib may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentobarbitalThe metabolism of Ruxolitinib can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Ruxolitinib can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Ruxolitinib can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ruxolitinib.Approved, Investigational
PindololRuxolitinib may increase the bradycardic activities of Pindolol.Approved
Poractant alfaRuxolitinib may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe serum concentration of Ruxolitinib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe metabolism of Ruxolitinib can be increased when combined with Primidone.Approved, Vet Approved
PropafenoneRuxolitinib may increase the bradycardic activities of Propafenone.Approved
PropranololRuxolitinib may increase the bradycardic activities of Propranolol.Approved, Investigational
Rabies vaccineThe risk or severity of adverse effects can be increased when Ruxolitinib is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Ruxolitinib.Approved
RanolazineThe metabolism of Ruxolitinib can be decreased when combined with Ranolazine.Approved, Investigational
RifabutinThe metabolism of Ruxolitinib can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Ruxolitinib can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ruxolitinib can be increased when combined with Rifapentine.Approved
RitonavirThe serum concentration of Ruxolitinib can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineRuxolitinib may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Ruxolitinib.Approved
SaquinavirThe serum concentration of Ruxolitinib can be increased when it is combined with Saquinavir.Approved, Investigational
SildenafilThe metabolism of Ruxolitinib can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Ruxolitinib can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Ruxolitinib can be increased when it is combined with Simeprevir.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ruxolitinib.Approved
SotalolRuxolitinib may increase the bradycardic activities of Sotalol.Approved
SRP 299The risk or severity of adverse effects can be increased when Ruxolitinib is combined with SRP 299.Investigational
St. John's WortThe serum concentration of Ruxolitinib can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StiripentolThe serum concentration of Ruxolitinib can be increased when it is combined with Stiripentol.Approved
SufentanilRuxolitinib may increase the bradycardic activities of Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Ruxolitinib can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Ruxolitinib.Approved, Investigational
TelaprevirThe serum concentration of Ruxolitinib can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Ruxolitinib can be increased when it is combined with Telithromycin.Approved
TG4010The risk or severity of adverse effects can be increased when Ruxolitinib is combined with TG4010.Investigational
TiclopidineThe metabolism of Ruxolitinib can be decreased when combined with Ticlopidine.Approved
TimololRuxolitinib may increase the bradycardic activities of Timolol.Approved
TizanidineRuxolitinib may increase the bradycardic activities of Tizanidine.Approved
TocilizumabThe serum concentration of Ruxolitinib can be decreased when it is combined with Tocilizumab.Approved
TofacitinibRuxolitinib may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Ruxolitinib.Approved, Investigational
VenlafaxineThe metabolism of Ruxolitinib can be decreased when combined with Venlafaxine.Approved
VerapamilRuxolitinib may increase the bradycardic activities of Verapamil.Approved
VoriconazoleThe serum concentration of Ruxolitinib can be increased when it is combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Ruxolitinib can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Take without regards to meals
References
Synthesis ReferenceNot Available
General References
  1. Cervantes F, Martinez-Trillos A: Myelofibrosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother. 2013 May;14(7):873-84. doi: 10.1517/14656566.2013.783019. Epub 2013 Mar 21. [PubMed:23514013 ]
  2. Yang LP, Keating GM: Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012 Nov 12;72(16):2117-27. doi: 10.2165/11209340-000000000-00000. [PubMed:23061804 ]
External Links
ATC CodesL01XE18
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (399 KB)
MSDSDownload (210 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9673
Caco-2 permeable-0.5198
P-glycoprotein substrateNon-substrate0.7838
P-glycoprotein inhibitor INon-inhibitor0.8228
P-glycoprotein inhibitor IIInhibitor0.7092
Renal organic cation transporterNon-inhibitor0.5098
CYP450 2C9 substrateNon-substrate0.8394
CYP450 2D6 substrateNon-substrate0.8075
CYP450 3A4 substrateNon-substrate0.6535
CYP450 1A2 substrateInhibitor0.6426
CYP450 2C9 inhibitorNon-inhibitor0.7731
CYP450 2D6 inhibitorNon-inhibitor0.9208
CYP450 2C19 inhibitorNon-inhibitor0.6689
CYP450 3A4 inhibitorNon-inhibitor0.6655
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5753
Ames testAMES toxic0.5681
CarcinogenicityNon-carcinogens0.9308
BiodegradationNot ready biodegradable0.9917
Rat acute toxicity2.5724 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.633
hERG inhibition (predictor II)Non-inhibitor0.8772
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral10 mg/1
TabletOral15 mg/1
TabletOral20 mg/1
TabletOral25 mg/1
TabletOral5 mg/1
TabletOral10 mg
TabletOral15 mg
TabletOral20 mg
TabletOral5 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7598257 No2007-12-242027-12-24Us
US8415362 No2007-12-242027-12-24Us
US8722693 No2008-06-122028-06-12Us
US8822481 No2008-06-122028-06-12Us
US8829013 No2008-06-122028-06-12Us
US9079912 No2006-12-122026-12-12Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySoluble in aqueous buffers across a pH of 1-8FDA label.
Predicted Properties
PropertyValueSource
Water Solubility0.116 mg/mLALOGPS
logP2.94ALOGPS
logP2.48ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)13.89ChemAxon
pKa (Strongest Basic)5.51ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area83.18 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity98.01 m3·mol-1ChemAxon
Polarizability33.04 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyrrolopyrimidines. These are compounds containing a pyrrolopyrimidine moiety, which consists of a pyrrole ring fused to a pyrimidine. Pyrrole is 5-membered ring consisting of four carbon atoms and one nitrogen atom. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyrrolopyrimidines
Sub ClassNot Available
Direct ParentPyrrolopyrimidines
Alternative Parents
Substituents
  • Pyrrolopyrimidine
  • Pyrimidine
  • Heteroaromatic compound
  • Pyrrole
  • Pyrazole
  • Azole
  • Azacycle
  • Nitrile
  • Carbonitrile
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Ubiquitin protein ligase binding
Specific Function:
Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway. Kinase partner for the interleukin (IL)-2 receptor.
Gene Name:
JAK1
Uniprot ID:
P23458
Molecular Weight:
133275.995 Da
References
  1. Cervantes F, Martinez-Trillos A: Myelofibrosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother. 2013 May;14(7):873-84. doi: 10.1517/14656566.2013.783019. Epub 2013 Mar 21. [PubMed:23514013 ]
  2. Yang LP, Keating GM: Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012 Nov 12;72(16):2117-27. doi: 10.2165/11209340-000000000-00000. [PubMed:23061804 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sh2 domain binding
Specific Function:
Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR)...
Gene Name:
JAK2
Uniprot ID:
O60674
Molecular Weight:
130672.475 Da
References
  1. Cervantes F, Martinez-Trillos A: Myelofibrosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother. 2013 May;14(7):873-84. doi: 10.1517/14656566.2013.783019. Epub 2013 Mar 21. [PubMed:23514013 ]
  2. Yang LP, Keating GM: Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012 Nov 12;72(16):2117-27. doi: 10.2165/11209340-000000000-00000. [PubMed:23061804 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Yang LP, Keating GM: Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012 Nov 12;72(16):2117-27. doi: 10.2165/11209340-000000000-00000. [PubMed:23061804 ]
Comments
comments powered by Disqus
Drug created on May 13, 2013 12:21 / Updated on December 06, 2016 02:42